Gene · 79679
Papers2,409
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,001 to 1,020 of 2,409
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Development and Verification of a Hypoxic Gene Signature for Predicting Prognosis, Immune Microenvironment, and Chemosensitivity for Osteosarcoma. | Front Mol Biosci | 2021 | 35071320 | PubTator, text mining | PubMed |
| Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. | Front Cell Dev Biol | 2021 | 35071240 | PubTator, text mining | PubMed |
| A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma. | Front Genet | 2021 | 35069695 | PubTator, text mining | PubMed |
| Detecting the differential genomic variants using cross-population phenotype-associated variant (XP-PAV) of the Landrace and Yorkshire pigs in Korea. | Anim Cells Syst (Seoul) | 2021 | 35059141 | PubTator, text mining | PubMed |
| Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma. | Front Immunol | 2021 | 35003069 | PubTator, text mining | PubMed |
| Cytochrome b561 Serves as a Potential Prognostic Biomarker and Target for Breast Cancer. | Int J Gen Med | 2021 | 35002301 | PubTator, text mining | PubMed |
| Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer. | Front Immunol | 2021 | 34992609 | PubTator, text mining | PubMed |
| Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting. | Front Oncol | 2021 | 34988021 | PubTator, text mining | PubMed |
| A Novel Model of Tumor-Infiltrating B Lymphocyte Specific RNA-Binding Protein-Related Genes With Potential Prognostic Value and Therapeutic Targets in Multiple Myeloma. | Front Genet | 2021 | 34976013 | PubTator, text mining | PubMed |
| Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. | Nat Cancer | 2021 | 34966897 | PubTator, text mining | PubMed |
| Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1. | Front Oncol | 2021 | 34966689 | PubTator, text mining | PubMed |
| Genomics and Prognosis Analysis of N6-Methyladenosine Regulators in Lung Adenocarcinoma. | Front Genet | 2021 | 34956315 | PubTator, text mining | PubMed |
| Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies. | Front Immunol | 2021 | 34956172 | PubTator, text mining | PubMed |
| PD-1H Expression Associated With CD68 Macrophage Marker Confers an Immune-Activated Microenvironment and Favorable Overall Survival in Human Esophageal Squamous Cell Carcinoma. | Front Mol Biosci | 2021 | 34950702 | PubTator, text mining | PubMed |
| Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. | Int J Mol Sci | 2021 | 34948104 | PubTator, text mining | PubMed |
| Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis. | Diagnostics (Basel) | 2021 | 34943606 | PubTator, text mining | PubMed |
| The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. | J Hematol Oncol | 2021 | 34930377 | PubTator, text mining | PubMed |
| Identification and Validation of the lncRNA BACE1-AS as Immune-Related Influencing Factor in Tumorigenesis following Pan-Carcinoma Analysis. | J Immunol Res | 2021 | 34926701 | PubTator, text mining | PubMed |
| Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment. | BMC Pulm Med | 2021 | 34923982 | PubTator, text mining | PubMed |
| The Prognostic Value and Immune Landscapes of a m6A/m5C/m1A-Related LncRNAs Signature in Head and Neck Squamous Cell Carcinoma. | Front Cell Dev Biol | 2021 | 34917609 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/papers?page=51